General

In late 2023, a patient with type 2 diabetes asked ChatGPT whether semaglutide could eliminate the need for insulin entirely. […]

In 2023, a patient asked ChatGPT whether she could take Eliquis with ibuprofen. ChatGPT told her the combination was generally

How drug brands fought off-label prescribing to survive: real FDA cases, litigation wins, and what AI monitoring means for pharmacovigilance

There’s a strange thing that happens in antidepressant discussions: everyone talks about the start (the “it finally kicked in” moment),

There’s a quiet pattern in drug questions that shows up again and again: not “does it work?” but “what will

Nobody switches drugs because they want to. They switch because something stops working. If you strip away the clinical jargon

When a patient asks ChatGPT whether they should take Ozempic or Wegovy, they are not reading your brand’s prescribing information,

The medical science liaison had just finished a physician meeting when the rep on the account pulled out his phone.

A hospitalist in Cleveland needs to know the renal dosing adjustment for a patient on apixaban with a creatinine clearance

Clinical trials are tidy. Patients are not. In papers, drugs are taken on schedule, at fixed doses, with carefully controlled

A quiet tour through how drugs escape their instructions—and what that says about modern demand There’s a peculiar irony in

Side effects, safety signals, and the uncomfortable gap between “works” and “well tolerated” Drug development has a habit of looking